Ocular Therapeutix Soars 11.11% on Positive Analyst Coverage

On April 10, 2025, Ocular Therapeutix surged 11.11% in pre-market trading, marking a significant rise in investor interest and confidence in the company's prospects.

William Blair, a prominent investment firm, initiated coverage of Ocular Therapeutix with an Outperform rating and a fair value target of $18 per share. This positive outlook is driven by the company's lead asset, Axpaxli, a sustained-release hydrogel implant containing axitinib, which is currently in Phase III trials for neovascular age-related macular degeneration (nAMD).

The firm highlights that Ocular Therapeutix's long-acting therapeutic approach could revolutionize nAMD treatment, reducing the need for frequent injections. Axpaxli, part of the emerging tyrosine kinase inhibitor (TKI) class, aims to enhance both efficacy and treatment durability, positioning it as a potential best-in-class solution. Additionally, William Blair sees potential for Axpaxli's use to expand into other retinal vascular diseases, further bolstering the company's long-term opportunities.